Breast Tissue Chemistry Measured In Vivo In Healthy Women Correlate with Breast Density and Breast Cancer Risk.
breast density
cancer risk
cholesterol
in vivo MR spectroscopy
lipids
Journal
Journal of magnetic resonance imaging : JMRI
ISSN: 1522-2586
Titre abrégé: J Magn Reson Imaging
Pays: United States
ID NLM: 9105850
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
09
03
2022
received:
07
04
2021
accepted:
11
03
2022
pubmed:
24
3
2022
medline:
15
10
2022
entrez:
23
3
2022
Statut:
ppublish
Résumé
The relationship of tissue chemistry to breast density and cancer risk has not been documented despite breast density being a known risk factor. To investigate whether distinct chemical profiles associated with breast density and cancer risk are identified in healthy breast tissue using in vivo two-dimensional correlated spectroscopy (2D COSY). Prospective. One-hundred-seven participants including 55 at low risk and 52 at high risk of developing breast cancer. 3 T/ axial/ T1, T2, 2D COSY. Two radiologists defined breast density on T2. Interobserver variability assessed. Peak volumes normalized to methylene at (1.30, 1.30) ppm as internal shift reference. Chi-squared/Mann-Whitney/Kappa statistics/Kruskal Wallis/pairwise analyses. Significance level 0.05. Ten percentage were fatty breasts, 39% scattered fibroglandular, 35% heterogeneously dense, and 16% extremely dense. Interobserver variability was excellent (kappa = 0.817). Sixty percentage (64/107) were premenopausal. Four distinct tissue chemistry categories were identified: low-density (LD)/premenopausal, high-density (HD)/premenopausal, LD/postmenopausal, and HD/postmenopausal. Compared to LD, HD breast chemistry showed significant increases of cholesterol (235%) and lipid unsaturation (33%). In the low-risk category, postmenopausal women with dense breasts recorded the largest significant changes including cholesterol methyl 540%, lipid unsaturation 207%, glutamine/glutamate 900%, and choline/phosphocholine 800%. In the high-risk cohort, premenopausal women with HD recorded a more active chemical profile with significant increases in choline/phosphocholine 1100%, taurine/glucose 550% and cholesterol sterol 250%. Four distinct chemical profiles were identified in healthy breast tissue based on breast density and menopausal status in participants at low and high risk. Gradual increase in neutral lipid content and metabolites was noted in both risk groups across categories in different order. In low risk, the HD postmenopausal category exhibited the highest metabolic activity, while women at high risk exhibited the highest lipid content and metabolic activity in the HD premenopausal category. 2 TECHNICAL EFFICACY STAGE: 3.
Sections du résumé
BACKGROUND
The relationship of tissue chemistry to breast density and cancer risk has not been documented despite breast density being a known risk factor.
PURPOSE
To investigate whether distinct chemical profiles associated with breast density and cancer risk are identified in healthy breast tissue using in vivo two-dimensional correlated spectroscopy (2D COSY).
STUDY TYPE
Prospective.
POPULATION
One-hundred-seven participants including 55 at low risk and 52 at high risk of developing breast cancer.
FIELD STRENGTH/SEQUENCE
3 T/ axial/ T1, T2, 2D COSY.
ASSESSMENT
Two radiologists defined breast density on T2. Interobserver variability assessed. Peak volumes normalized to methylene at (1.30, 1.30) ppm as internal shift reference.
STATISTICAL TESTS
Chi-squared/Mann-Whitney/Kappa statistics/Kruskal Wallis/pairwise analyses. Significance level 0.05.
RESULTS
Ten percentage were fatty breasts, 39% scattered fibroglandular, 35% heterogeneously dense, and 16% extremely dense. Interobserver variability was excellent (kappa = 0.817). Sixty percentage (64/107) were premenopausal. Four distinct tissue chemistry categories were identified: low-density (LD)/premenopausal, high-density (HD)/premenopausal, LD/postmenopausal, and HD/postmenopausal. Compared to LD, HD breast chemistry showed significant increases of cholesterol (235%) and lipid unsaturation (33%). In the low-risk category, postmenopausal women with dense breasts recorded the largest significant changes including cholesterol methyl 540%, lipid unsaturation 207%, glutamine/glutamate 900%, and choline/phosphocholine 800%. In the high-risk cohort, premenopausal women with HD recorded a more active chemical profile with significant increases in choline/phosphocholine 1100%, taurine/glucose 550% and cholesterol sterol 250%.
DATA CONCLUSION
Four distinct chemical profiles were identified in healthy breast tissue based on breast density and menopausal status in participants at low and high risk. Gradual increase in neutral lipid content and metabolites was noted in both risk groups across categories in different order. In low risk, the HD postmenopausal category exhibited the highest metabolic activity, while women at high risk exhibited the highest lipid content and metabolic activity in the HD premenopausal category.
LEVEL OF EVIDENCE
2 TECHNICAL EFFICACY STAGE: 3.
Identifiants
pubmed: 35319148
doi: 10.1002/jmri.28168
pmc: PMC9790468
doi:
Substances chimiques
Glutamates
0
Lipids
0
Sterols
0
Glutamine
0RH81L854J
Phosphorylcholine
107-73-3
Taurine
1EQV5MLY3D
Glucose
IY9XDZ35W2
Choline
N91BDP6H0X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1355-1369Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Journal of Magnetic Resonance Imaging published by Wiley Periodicals LLC on behalf of International Society for Magnetic Resonance in Medicine.
Références
NMR Biomed. 2009 Jan;22(1):77-91
pubmed: 19086016
Eur J Biochem. 1992 Apr 15;205(2):827-39
pubmed: 1572374
Stat Med. 2004 Apr 15;23(7):1111-30
pubmed: 15057881
Methods Enzymol. 1986;128:472-515
pubmed: 3724520
Br J Cancer. 2010 Jan 5;102(1):42-7
pubmed: 19904271
PLoS One. 2010 Sep 22;5(9):e12811
pubmed: 20877640
NMR Biomed. 2002 Aug;15(5):327-37
pubmed: 12203224
Oncotarget. 2016 May 24;7(21):31550-62
pubmed: 26784251
Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1159-69
pubmed: 16775176
Pathology. 1993 Jul;25(3):268-76
pubmed: 7903445
Trends Biochem Sci. 1988 May;13(5):172-7
pubmed: 3255199
Front Endocrinol (Lausanne). 2019 Oct 30;10:703
pubmed: 31736870
Trends Biochem Sci. 2000 Aug;25(8):357-62
pubmed: 10916153
Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):243-8
pubmed: 11303594
Lancet. 2005 May 14-20;365(9472):1727-41
pubmed: 15894099
MAGMA. 1997 Jun;5(2):105-10
pubmed: 9268073
Angiogenesis. 2011 Sep;14(3):321-30
pubmed: 21553281
Breast Cancer Res Treat. 2011 Jul;128(2):505-16
pubmed: 21258862
EBioMedicine. 2016 Nov;13:146-156
pubmed: 27743905
Eur J Cancer. 2018 Jan;88:48-56
pubmed: 29190506
Eur Rev Med Pharmacol Sci. 2015 Nov;19(22):4419-26
pubmed: 26636532
Breast Cancer Res. 2018 Aug 9;20(1):92
pubmed: 30092832
J Magn Reson B. 1994 May;104(1):1-10
pubmed: 8025810
J Nucl Med. 2010 Mar;51(3):347-52
pubmed: 20150253
JAMA Netw Open. 2021 Aug 2;4(8):e2122810
pubmed: 34436608
NMR Biomed. 2009 Jan;22(1):54-64
pubmed: 19086012
FEBS Lett. 1991 Aug 5;287(1-2):97-101
pubmed: 1908793
CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89
pubmed: 17392385
N Engl J Med. 2007 Jan 18;356(3):227-36
pubmed: 17229950
Magn Reson Imaging. 2016 May;34(4):524-8
pubmed: 26712654
Oncoimmunology. 2016 Sep 2;5(10):e1229723
pubmed: 27853653
Breast J. 2009 Sep-Oct;15 Suppl 1:S33-8
pubmed: 19775328
Cancer Epidemiol Biomarkers Prev. 1998 Dec;7(12):1133-44
pubmed: 9865433
Int J Cancer. 1994 Oct 15;59(2):248-61
pubmed: 7927926
Nat Rev Cancer. 2011 Nov 17;11(12):835-48
pubmed: 22089420
J Biol Chem. 1978 Jun 10;253(11):3983-7
pubmed: 206556
Radiology. 2015 Jun;275(3):675-82
pubmed: 25734415